Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Cara Therapeutics doses first patient in study of CR-845

Oct. 26, 2017

FDA issues complete response letter for Xyosted

Oct. 23, 2017

Cara Therapeutics planning phase III pivotal program for CR-845

Oct. 17, 2017

Japan Tobacco enters licensing agreement for Rayaldee in Japan

Oct. 16, 2017

Vantia reports phase III topline data on fedovapagon for nocturia in men with BPH

Oct. 5, 2017

Soluble Nogo-B a potential treatment for diabetic glomerulopathy

Oct. 5, 2017

COLEC11, a possible therapeutic target for treating renal ischemia reperfusion injury

Oct. 2, 2017

First subject enrolled in phase III study of TRC-101 in chronic kidney disease

Sep. 29, 2017

The Brigham and Women's Hospital identifies SMOC2 inhibitors

Sep. 26, 2017

FDA accepts for review sNDA for mirabegron in combination with solifenacin for overactive bladder

Sep. 14, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...